Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 1

Demographic and clinical data of patients.

Variable	Group		Rivaroxaban	Warfarin	/	value
Sex	F	67	45 (52.33%)	22 (52.38%)	0.000	0.995
	M	61	41 (47.67%)	20 (47.62%)
Combined with DVT	Without	69	48 (55.81%)	21 (50%)	0.384	0.536
	With	59	38 (44.19%)	21 (50%)
HAS-BLED	Lower danger	122	85 (98.84%)	37 (88.1%)	7.288
	Higher danger	6	1 (1.16%)	5 (11.9%)
Risk stratification	Lower danger	27	22 (25.58%)	5 (11.9%)	0.384	0.536
	Intermediate-lower danger	60	46 (53.49%)	14 (33.33%)
	Intermediate-high danger	36	15 (17.44%)	21 (50%)
	Higher danger	5	3 (3.49%)	2 (4.76%)
Expected course of treatment	3 months	53	34 (39.53%)	19 (45.24%)	0.378	0.539
	6 months	75	52 (60.47%)	23 (54.76%)
Thrombolysis	Without	107	75 (87.21%)	32 (76.19%)	2.498	0.114
	With	21	11 (12.79%)	10 (23.81%)
Age	—	128			2.012
Weight	—	125^a			1.347	0.180
BMI	—	125^a			1.583	0.116
PESI	—	128			2.091
sPESI	—	128			0.711	0.478

^aMissing number is 3.